Regístrese
Buscar en
Allergologia et Immunopathologia
Toda la web
Inicio Allergologia et Immunopathologia Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous u...
Journal Information
Vol. 47. Issue 6.
Pages 515-522 (November - December 2019)
Share
Share
Download PDF
More article options
ePub
Vol. 47. Issue 6.
Pages 515-522 (November - December 2019)
Original Article
DOI: 10.1016/j.aller.2019.05.003
Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis
Visits
0
N.P.M. Rubinia, L.F.C. Ensinab, E.M.K. Silvac, F. Sanod, D. Solée,
Corresponding author
dirceu.sole@unifesp.br

Corresponding author at: Rua dos Otonis 725, Vila Clementino, São Paulo 04025-002, SP, Brazil.
a School of Medicine and Surgery, Federal University of the State of Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil
b Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Escola Paulista de Medicina, Federal University of São Paulo (EPM-UNIFESP), São Paulo, Brazil
c Division of Emergency and Evidence Based Medicine, EPM-UNIFESP and Researcher of Cochrane Center of Brazil, São Paulo, Brazil
d Nipo-Brazilian Hospital, São Paulo, Brazil
e Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, EPM-UNIFESP, São Paulo, Brazil
This item has received
0
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (2)
Table 1. Characteristics of the studies included in the meta-analysis.
Table 2. Summary of the meta-analyses of Omalizumab 300mg in the treatment of Chronic Spontaneous Urticaria.
Show moreShow less
Abstract
Introduction

Chronic spontaneous urticaria (CSU) affects approximately 1% of the population, affecting both children and adults. Omalizumab (Oma) is a therapeutic option for patients with refractory forms of CSU.

Objectives

To determine the effectiveness and safety of Oma in the treatment of CSU.

Methods

Systematic review (Cochrane Collaboration methodology) of randomized clinical trials comparing Oma to placebo in refractory CSU treatment. The search is based on MEDLINE; EMBASE, Central Cochrane Library, and LILACS. The outcomes evaluated were: control of the illness, adverse events, and quality of life.

Results

Of the 848 identified studies 13 were selected for further review and six were included in the meta-analysis. For all outcomes, high-quality evidence has confirmed that Oma is effective in the treatment of CSU. The dosage of 300mg/month achieved better results; namely a significant reduction in pruritus, papules, and urticaria activity, as well as an increase in the number of patients with a controlled condition, improvement in the quality of life and no differences in adverse events compared to the placebo.

Conclusions

High-quality evidence demonstrates that Oma is effective and safe in the treatment of CSU refractory to therapy with H1 antihistamines.

Keywords:
Omalizumab
anti-IgE monoclonal antibody
anti-IgE
Chronic urticaria

Article

These are the options to access the full texts of the publication Allergologia et Immunopathologia
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Allergologia et Immunopathologia

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.